Piper Sandler raised the firm’s price target on Bristol Myers (BMY) to $66 from $62 and keeps an Overweight rating on the shares. The firm says Bristol continues to profile as inexpensive, with the shares essentially pricing in the eventual Eliquis U.S. LOE, but not adequately reflecting what in Piper’s view is growing visibility into a return to growth on the back of steady pipeline advancement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target raised to $60 from $53 at Citi
- Bristol-Myers Squibb Advances Repotrectinib Interaction Study: What Investors Should Know
- Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig
- Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
- Bristol Myers Squibb Advances Opdivo/Yervoy in China Mesothelioma Trial, Signaling New Oncology Upside